

Coulter:Partners

Top hires for VC & PE portfolio companies Q4-2020

Search Highlights

This quarter's successful placements include:

- CEO, drug delivery systems, Germany
- CEO, medical implants, France
- CEO, women's health, Switzerland/ US
- Chief Commercial Officer, CNS diseases, US
- Chief Financial Officer, clinical research services, Europe
- Chief Medical Officer, haemostasis therapeutics, Netherlands
- Chief Scientific Officer, vaccines, Switzerland
- Head of Growth/ Chief Marketing Officer, digital health, Germany
- VP Research, stem cell therapy, UK
- VP Sales & Marketing US, genome editing technology, Ireland
- VP Commercial Europe, in vitro diagnostic products, Israel
- Head of Regulatory Affairs US, rare diseases, Switzerland
- Head of Business Development US, CDMO, France
- GM Tissues and Biologics, medical devices, US
- Head of M&A DACH, animal health, Nordics
- Director Human Resources, nanoparticle medicine, Nordics
- Associate, life science VC, Netherlands
- Board Director, regenerative therapeutic biologics, US
- Board Director, vaccines, DACH

Newly opened projects include:

- CEO, dental implants, Benelux
- CEO, microbiome-based therapeutics, US
- Chief Medical Officer, vaccines, Nordics
- Chief Business Officer, oncology, Switzerland
- VP R&D, neurodegenerative diseases, US
- Group VP Technical Development, CDMO, Eastern Europe
- Head of Business Development, AI for drug discovery, UK
- VP Quality & Regulatory Affairs, medical devices, UK
- Senior US Venture Partner, life science VC, UK
- Partner, life science investor, Belgium

Themes

Areas of focus this quarter include, but are not limited to:

- Rare diseases
- Vaccines
- Oncology
- Neurology
- Artificial Intelligence
- P.O.C. diagnostics
- Cardiovascular
- Animal health
- Dental
- Gene therapy
- Women's health
- Venture teams

www.coulterpartners.com